HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors-Reference-Cited by-同舟云学术

HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors

Published:2018-09-04 Issue:10 Volume:31 Page:1022-1024
ISSN:0893-228X
Container-title:Chemical Research in Toxicology
language:en
Short-container-title:Chem. Res. Toxicol.

Author:

Usui Toru¹,Tailor Arun¹,Faulkner Lee¹,Meng Xiaoli¹^ORCID,Farrell John¹,Daly Ann K.²,Dear Gordon J.³,Park B. Kevin¹,Naisbitt Dean J.¹^ORCID

Affiliation:

1. MRC Center for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool, L69 3GE, England

2. Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle NE2 4HH, United Kingdom

3. GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 7BB, United Kingdom

Funder

Medical Research Council

European Commission

GlaxoSmithKline

European Federation of Pharmaceutical Industries and Associations

Publisher

American Chemical Society (ACS)

Subject

Toxicology,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.chemrestox.8b00163

Reference9 articles.

1. Patient characteristics in ticlopidine hydrochloride-induced liver injury: Case–control study

2. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case–control study

3. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study

4. Promiscuous T-cell responses to drugs and drug-haptens

5. From the Cover: Characterization of Isoniazid-Specific T-Cell Clones in Patients with anti-Tuberculosis Drug-Related Liver and Skin Injury

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A blinded in vitro analysis of the intrinsic immunogenicity of hepatotoxic drugs: implications for preclinical risk assessment;Toxicological Sciences;2023-10-03

2. Genetics of drug‐induced liver injury: Current knowledge and future prospects;Clinical and Translational Science;2022-10-04

3. Molecular fingerprinting by single cell clone analysis in adverse drug reaction (ADR) assessment;Current Drug Safety;2021-07-27

4. Genetic risk factors in the development of idiosyncratic drug-induced liver injury;Expert Opinion on Drug Metabolism & Toxicology;2020-12-14

5. Pharmacogenomics of Drug-Induced Liver Injury;Advances in Molecular Pathology;2020-11